Grazoprevir Production Cost Reports

The report provides a detailed analysis essential for establishing a Grazoprevir manufacturing plant. It encompasses all critical aspects necessary for Grazoprevir production, including the cost of Grazoprevir production, Grazoprevir plant cost, Grazoprevir production costs, and the overall Grazoprevir manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Grazoprevir production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Grazoprevir is an antiviral medication used to treat Hepatitis C infection that affects the liver. It functions by preventing the hepatitis C virus from using specific proteins (NS3/4A proteases) to multiply and propagate throughout the body. Grazoprevir aids in preventing the virus from spreading and inflicting additional harm to the liver by blocking these proteins. Grazoprevir is mainly used in combination with another antiviral medication called elbasvir. This combination therapy, known as Zepatier, is highly effective in treating chronic hepatitis C infections, especially those caused by genotypes 1 and 4.

The procurement of Grazoprevir is influenced by its application in the pharmaceutical and medical industries as an antiviral medication used to treat Hepatitis C infection. The use of Grazoprevir has been demanded more since cases of Hepatitis C infections are rising. The combination of Grazoprevir and elbasvir shows a sustained virologic response (SVR), meaning the virus is no longer detectable in the blood in up to 99% of the patients. Most patients report minimal to no side effects from this well-tolerated medication.

Long-term health benefits of the medicine have been demonstrated, such as decreased risk of liver cancer, enhanced quality of life, decreased liver damage, and decreased overall mortality rates. Grazoprevir needs to be administered only once daily, which increases patient adherence. Overall, industrial Grazoprevir procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of Hepatitis C infection, combination therapy, fewer side effects, better tolerability, patient adherence, long-term health benefits, increasing healthcare awareness, and regulatory approvals.

Raw Material for Grazoprevir Production

According to the Grazoprevir manufacturing plant project report, the key raw material used in the production of Grazoprevir includes (1R,2R)-2-(pent-4-yn-1-yl) cyclopropane-1-ol.

Manufacturing Process of Grazoprevir

The extensive Grazoprevir production cost report consists of the following major industrial manufacturing process:

• Preparation from (1R,2R)-2-(pent-4-yn-1-yl) cyclopropane-1-ol: The manufacturing process of Grazoprevir starts with the reaction of the starting compound with (S)-2-amino-3,3-dimethylbutanoic acid in the presence of N, N′-carbonyl diimidazole (CDI), N, N-diisopropylethylamine (DIPEA) to give an alkyne intermediate. The intermediate is subjected to Sonogashira cross-coupling with quinoxaline to form another intermediate. The triple bond in the intermediate undergoes hydrogenation to form the third intermediate. The intermediate undergoes deprotection with PhSO3H, followed by intramolecular condensation to form the final intermediate. Finally, the compound undergoes hydroxylation and condensation in the presence of ethyl dichloride, pyridine, and methyl cyanide to produce Grazoprevir.

Grazoprevir, commercially known as Zepatier (combination of Grazoprevir and elbasvir), appears to be a white to off-white solid having the molecular formula C38H50N6O9S and a molecular weight of 766.9 g/mol. It has limited water solubility of around 0.0108 mg/mL. It has a log P value of 3.26. The value of its dissociation constant, pKa, is 3.77. Adults with chronic HCV genotypes 1 or 4 infection are treated with azamacrocyclic drug Grazoprevir, a hepatitis C protease inhibitor.